FDA Grants Orphan Drug Designation to Zenocutuzumab‑zbco for NRG1+ CCA The FDA has granted Orphan Drug Designation to zenocutuzumab-zbco (Bizengri) for advanced NRG1 fusion-positive cholangiocarcinoma (CCA).

The @fda.gov has granted #OrphanDrug Designation to zenocutuzumab-zbco (#Bizengri®) for adults with advanced unresectable or metastatic neuregulin 1 (#NRG1) gene fusion-positive #Cholangiocarcinoma (#CCA), according to a recent press release.

Read here: https://bit.ly/4apGNlR

#RareDisease #MedSky

Promising Efficacy of Zenocutuzumab in Treatment-Naïve NRG1+ NSCLC Patients Discussed at IASLC-ASCO NACLC Recent findings on zenocutuzumab-zbco reveal durable efficacy in treatment-naïve NRG1+ non-small cell lung cancer, showcasing impactful results from the eNRGy trial.

Promising Efficacy of Zenocutuzumab in Treatment-Naïve NRG1+ NSCLC Patients Discussed at IASLC-ASCO NACLC #NSCLC #company_number #BIZENGRI #NRG1

New Research on Zenocutuzumab-zbco Marks a Breakthrough in NRG1+ Cancer Treatment A landmark study published in NEJM reveals the effectiveness of Zenocutuzumab-zbco (BIZENGRI®) for treating NRG1+ cancers, offering new hope to patients.

New Research on Zenocutuzumab-zbco Marks a Breakthrough in NRG1+ Cancer Treatment #USA #Lexington #NEJM #BIZENGRI #Zenocutuzumab

FDA Approves Bizengri for Targeted Therapy in Advanced Pancreatic and Lung Cancer Merus has achieved a significant milestone with the FDA’s accelerated approval of Bizengri (zenocutuzumab-zbco), making it the first-ever approved treatment for advanced pancreatic adenocarcinoma and ...

www.linkedin.com/pulse/fda-ap...

FDA Approves Bizengri for Targeted Therapy in Advanced Pancreatic and Lung Cancer

kstrategyand.com/pharma-news

#Bizengri #FDAApproval #AdvancedPancreaticCancer #NSCLC #CancerTreatment #TargetedTherapy #NRG1GeneFusion #Humanteconomy #Humantec #KStrategyand

Weekly Roundup - PHARMA - 23 December 2024 🔊 Merus's Bizengri Secures FDA Approval for Advanced Pancreatic Cancer and NSCLC The FDA's approval of Bizengri introduces the first U.S.

Weekly Roundup - PHARMA - 23 December 2024

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#Merus #Bizengri #FDA #Breckenridge #IonisPharmaceuticals #FDA #Checkpoint #Unloxcyt #Xcovery #Ensacove #Biotech #Pharma #Healthcare #ClinicalTrials #Humanteconomy #Humantec #KStrategyand

A new kind of cancer drug has received accelerated FDA approval: #Bizengri (zenocutuzumab, a HER2 x HER3 bispecific antibody) for treating advanced lung or pancreatic cancer with NRG1 gene rearrangements. www.fda.gov/drugs/resour...